Biote Corp posted an updated investor presentation on April 3, 2026, highlighting its 2025 financial performance, business model, and expansion opportunities in therapeutic wellness.
Key takeaways
Biote reported 2025 revenue of $192.2 million and adjusted EBITDA of $53.5 million with a 27.8% margin.
The company has over 9,200 certified practitioners and approximately 400,000 active patients as of December 31, 2025.
Biote is expanding beyond hormone optimization into new therapeutic wellness categories including weight loss, sexual health, and aesthetics.
The company repurchased approximately 5.5 million shares of its Class V voting stock for $25.1 million.
Biote operates in large addressable markets including a $400+ billion therapeutic wellness market and $7+ billion hormone replacement market.